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Abstract Early infection after stroke is associated with a poor
outcome. We aimed to determine whether delayed infections
(up to 76 days post-stroke) are associated with poor outcome
at 90 days. Data came from the international Efficacy of Nitric
Oxide Stroke (ENOS, ISRCTN99414122) trial. Post hoc data
on infections were obtained from serious adverse events re-
ports between 1 and 76 days following stroke in this large
cohort of patients. Regression models accounting for baseline
covariates were used to analyse fatalities and functional
outcomes (modified Rankin Scale (mRS), Barthel Index,
Euro-Qol-5D) at 90 days, in patients with infection compared
to those without infection. Of 4011 patients, 242 (6.0%) de-
veloped one or more serious infections. Infections were asso-
ciated with an increased risk of death (p < 0.001) and an
increased likelihood of dependency (measured by mRS) com-
pared to those of all other patients (p < 0.001). This remained
when only surviving patients were analysed, indicating that
the worsening of functional outcome is not due to mortality
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(p < 0.001). In addition, the timing of the infection after stroke
did not alter its detrimental association with fatality (p = 0.14)
or functional outcome (p = 0.47). In conclusion, severe post-
stroke infections, whether occurring early or late after stroke,
are associated with an increased risk of death and poorer func-
tional outcome, independent of differences in baseline charac-
teristics or treatment. Not only are strategies needed for reduc-
ing the risk of infection immediately after stroke, but also
during the first 3 months following a stroke. This study is
registered: ISRCTN registry, number ISRCTN99414122,
ClinicalTrials.gov Identifier, NCT00989716.
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Introduction
Approximately 15 million people in the world have a stroke
each year [1]. Of these, 30.0% will develop infections in the
first week post-stroke [2], which is associated with an increase
in the likelihood of death [3, 4] and the extent of disability [5,
6]. These data, combined with the growing body of evidence
from other neurological disorders, indicate that infection has a
detrimental effect on the damaged brain [7, 8].
The risk of infection is increased after a stroke due to im-
munosuppression [9, 10], dysphagia and aspiration [11],
cannulation/catherisation [12] and reduced mobility [13].
However, only a few studies have examined the effect of in-
fections beyond the first 14 days after a stroke, and these
showed that infections in the period from 14 up to 30 days
post-stroke were associated with increased dependence on
hospital discharge and increased mortality [14, 15].
The international multicentre Efficacy of Nitric Oxide in
Stroke (ENOS) trial [16] collected data on all serious adverse
events until 90 days post-randomisation, including common
infections such as pneumonia and urinary tract infections [17].
Using the data collected in this trial, we aimed to perform a
post hoc examination of the effect of infection up to 76 days
post-stroke on survival and functional outcome and quality of
life at 90 days post-randomisation.
Methods
ENOS Trial
The ENOS was an international multicentre trial of transder-
mal glyceryl trinitrate (GTN) or no GTN [16] in patients with
acute ischaemic stroke and high blood pressure. Those taking
antihypertensive medication were also randomised to contin-
ue or temporarily stop their medication in a partial factorial
design. Patients were randomised within 48 h of stroke onset
and treated for 7 days. This study is registered: ISRCTN
registry, number ISRCTN99414122, ClinicalTrials.gov
Identifier, NCT00989716.
Data collection for the ENOSwas performed using a secure
web interface and included the collection of baseline demo-
graphic (age, sex) and clinical variables (comorbidities, stroke
type, subtype and severity [Scandinavian Stroke Scale, SSS]).
Baseline data and main results have been reported previously
[16, 18].
Target Population for the Present Analysis
In addition to the ENOS exclusion criteria [16, 19], the fol-
lowing patients were excluded (Fig. 1): those with a previous
stroke (to reduce chance of patients having previous disability/
dependency), those with a non-stroke diagnosis and patients
with serious adverse events (SAEs) reported after 76 days (in
an attempt to prevent SAEs directly affecting outcome at
90 days). SAEs were defined as those events that were fatal,
caused disability, were life-threatening, led to hospital admis-
sion, prolonged discharge in a hospitalised patient or were
associated with birth defects in a child born to a trial
Fig. 1 Criteria used for selection of patients for analysis of the effects of
infection. Patients were excluded due to lack of defined stroke type,
previous stroke or serious adverse events (SAEs) after 76 days.
Remaining patients were grouped based on the absence of SAEs or the
presence of infections, secondary stroke-related cerebral events
(SSRCEs) or other SAEs. Patients with infections were compared to all
three of the other patient groups (individually or combined (termed: all
other patients)) to assess the effect of infection on case fatality and
functional outcome
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participant (http://www.nottingham.ac.uk/~nszwww/enos/
enosprotocolv15.pdf). SAEs that arose at any time point
from the randomisation to final follow-up at day 90 were
adjudicated blinded to treatment assignment by Daniel
Bereczki and Nikola Sprigg.
Patients included in the analysis were grouped based on the
presence of different types of SAEs. SAEs were categorised as
infection, secondary stroke-related cerebral event (SSRCE) or
other SAE. SSRCE was defined as cerebral oedema, compli-
cation or extension of initial stroke, haemorrhagic transforma-
tion, intracerebral/extracerebral/intracranial bleeds, transient
ischaemic attack or recurrent stroke. These are known towors-
en the outcomes being measured. Other SAEs included any
other event ranging from falls to cardiac events
(Supplementary Table I). Patients with no reported SAEs but
who had died by 90 days (as determined by the outcome
measures) were also placed in the other SAE category.
Patients with multiple SAEs were categorised as SSRCEs (if
they had at least one SSRCE) or infection (if they had no
SSRCEs, but had infection). Patients with infection were also
categorised by their time of presentation after randomisation:
within 7 days (early), 8–28 days (intermediate) and 29–
76 days (late). This was to allow the effect of infections ac-
quired at different time points to be delineated.
Outcome Measures
The outcome measures were case fatalities (by 90 days),
functional/vital status as measured by the modified Rankin
Scale (mRS, primary outcome) and activities of daily living
(Barthel Index and Euro-QoL-5D Health Utility State [HUS]).
The telephone-Mini Mental State Examination (t-MMSE),
modified Zung Depression Scale (ZDS), modified
Telephone Interview for Cognitive Status (TICS-M),
EuroQol-Visual Analogue Scale (EQ-VAS) and verbal fluen-
cy (animals named in 1 min) were also assessed in the ENOS
trial but not used in the analysis due to insufficient numbers of
responses in the subgroups (<20). All functional measures
were determined by telephone at 90 days by an assessor
blinded to treatment and other clinical details.
Statistics
All analyses were performed using SPSS, version 22. Data are
number (%), mean (standard deviation, SD) or median (inter-
quartile range, IQR). Significance is taken at p < 0.05.
Adjustments for multiplicity of testing were not performed.
Case fatalities in patients with infections were compared to
fatalities in all other patients, or to patients with either
SSRCEs or other SAEs using Cox regression with infection,
SSRCEs and other SAEs as time-updated covariates. This
second analysis allowed patients with infection to be com-
pared to other patient groups of a similar size whom also
experienced serious adverse events. To control for factors
which are known to alter outcome, other covariates were also
included in these analyses: age, sex, hypertension, diabetes,
use of alteplase, stroke type and severity at baseline, and the
ENOS treatment groups. An additional model (analysing just
patients with infection) was used to assess the effect of time of
infection on fatality across the patient group.
Functional outcome (mRS, Barthel Index and HUS) in pa-
tients with infection and all other patients (without SAEs, with
SSRCEs or with other SAEs) was analysed using ordered
probit regression. The covariates described above were in-
cluded in the analysis. Ordered probit regression was repeated
using only patients who survived to 90 days in order to sepa-
rate the effect of infection on functional outcome from that on
mortality, as the functional outcome measures included death
in the scoring system. To assess if the time that infection
developed influenced outcome within the surviving popula-
tion, regressions compared functional outcome in patients ac-
quiring infections at each time points (1–7, 8–28 and 29–
76 days post-stroke) to functional outcome in all other pa-
tients. An additional model (analysing just patients with infec-
tion) was used to assess the effect of time of infection on
dependency across the patient group. To control further for
baseline differences and confirm the findings of regression
analysis, patients with infections were paired with those that
had no SAEs. These paired groups were compared using or-
dered probit regression without covariates (see Supplemental
Table II and Figure II for full details).
Results
Participants and SAE Occurrence
Of the 4011 patients enrolled into the ENOS trial, 703 were
excluded from this analysis. Of the remaining patients, 760
developed SAEs with 1091 SAEs reported in total. Two hun-
dred ninety-three (26.9%) of these SAEs were infections,
which occurred in 242 patients. Thirty of these patients were
removed from the infection group due to the additional pres-
ence of a SSRCE. Out of the 293 reported infections, 192
(65.5%) were pneumonia and 57 (19.5%) were urinary tract
infections. Of the remaining SAEs reported, 260 (23.8%) were
SSRCEs and 538 (49.3%) were other SAEs occurring in 242
and 306 patients, respectively. The characteristics of patients
with infections, SSRCEs, other SAEs or no SAEs are shown
in Table 1.
The incidence rate of infections, SSRCEs and other SAEs
followed a non-linear pattern with more SAEs reported shortly
after stroke onset. The median number of days between stroke
onset and SAE occurrence was 4 (2–12) days for SSRCEs, 11
(3–32) days for infections and 14 (4–33) days for other SAEs.
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Case Fatality Rate in Patients with Infections, SSRCEs
or Other SAEs
Infections significantly increased the likelihood of fatality
(Fig. 2a; hazard ratio [HR] = 6.47, 95% confidence interval
[CI] = 5.01–8.35, p < 0.001) compared to all patients, irre-
spective of other covariates. When compared to SSRCEs or
other SAEs (Fig. 2b), both infections (HR = 1.94, 95%
CI = 1.50–2.51, p < 0.001) and SSRCEs (HR = 2.02, 95%
CI = 1.53–2.68, p < 0.001) increased the likelihood of fatality.
The occurrence of other SAEs did not affect fatality rate
(HR = 0.83, 95% CI = 0.62–1.10, p = 0.19). Analysis of the
infection group alone showed that the timing of infection did
not affect fatality (HR = 0.99, 95% CI = 0.99–1.00, p = 0.14),
indicating that late infections were as likely to cause death as
those presenting in the days after stroke. In addition, 58.4% of
patients destined to die after their infection did so in the first
2 days (Supplementary Figure I).
Functional Outcome in Patients with Infection
Infections significantly increased the likelihood of dependen-
cy as measured by the mRS (Fig. 3a; odds ratio [OR] = 2.90,
95% CI = 2.46–3.42, p < 0.001) compared to that of all other
patients irrespective of other covariates. This finding was also
present for the Barthel Index (Table 2, OR = 0.34, 95%
Table 1 Baseline characteristics
of all patients in the ENOS
trial and groups of patients used in
this study
Variable All patients Patients with:
Infections SSRCEs Other SAEs No SAEs
No. of patients 4011 212 242 306 2524
Age (years) 70.3 (12.2) 77.8 (9.9) 72.5 (12.7) 72.7 (11.1) 68.7 (12.1)
Sex, male 2297 (57.3%) 118 (55.7%) 119 (49.2%) 157 (51.3%) 1486 (58.9%)
Risk factors
Hypertension 2607 (65.0%) 134 (63.2%) 165 (68.2%) 195 (63.7%) 1549 (61.4%)
Diabetes 699 (17.4%) 35 (16.5%) 48 (19.8%) 45 (14.7%) 396 (15.7%)
Thrombolysis 425 (10.6%) 27 (12.7%) 32 (13.2%) 45 (14.7%) 252 (10.0%)
Stroke type
Ischaemic 3342 (83.3%) 181 (85.4%) 197 (81.4%) 275 (89.9%) 2097 (83.1%)
Haemorrhagic 629 (15.7%) 31 (14.6%) 45 (18.6%) 31 (10.1%) 427 (16.9%)
Pre-morbid mRS 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–0)
SSS score (/58) 36 (24–44) 22 (12–30) 26 (14–39) 32 (21–41) 38 (28–46)
GTN treatment 2000 (49.9%) 108 (50.9%) 135 (55.8%) 167 (54.6%) 1230 (48.7%)
Time to treatment 26.0 (12.9) 27.7 (12.6) 23.7 (12.8) 25.6 (14.2) 26.2 (12.7)
Developed SAEs 1057 (26.4%)
Death by 90 days 494 (12.3%) 113 (53.3%) 125 (51.9%) 91 (29.7%) 0 (0%)
Data is described as number (% of patients in group) for categorical data, mean (SD) for continuous data or
median (IQR) for ordinal data
SSRCEs secondary stroke-related cerebral events, SAEs serious adverse events, SSS Scandinavian Stroke Scale,
GTN glyceryl trinitrate
Fig. 2 Descriptive Kaplan-Meier graphs for patients developing
infections between 1 and 76 days post-stroke and other groups of
patients. a Patients with infections (n = 212) in comparison to all other
patients (after exclusions, n = 3072). b Patients with infections in
comparison to those with secondary stroke-related cerebral events
(SSRCEs, n = 242) or with other serious adverse events (SAEs, n = 306)
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CI = 0.28–0.40, p < 0.001) and the HUS (OR = 0.62, 95%
CI = 0.53–0.72, p < 0.001).
To establish that the reduction in functional outcome was
not simply due to the increased mortality in the infection
group, as the functional outcome measures include death as
a score, the analysis was repeated using only patients who
survived until 90 days. Patients who had infections continued
to exhibit a significantly worse functional outcome overall, as
measured by the mRS (Fig. 3, OR = 1.71, 95% CI = 1.37–
2.14, p < 0.001), than patients with no SAE. This difference
was evident for infections between 1 and 7 days post-stroke
(OR = 1.89, 95% CI = 1.38–2.58, p < 0.001), 8–28 days post-
stroke (OR = 1.79, 95% CI = 1.15–2.80, p = 0.010) and 29–
76 days post-stroke (OR = 1.56, 95% CI = 1.00–2.43,
Fig. 3 Distributions in modified Rankin Scale scores at day 90 for stroke
patients with infections and all other patients. a All patients with serious
adverse events (SAEs) between 1 and 76 days post-stroke and patients
without SAEs. b Patients who survived to 90 days only. c Surviving
patients were split into patients who acquired infections or other SAEs
between 1–7, 8–28 and 29–76 days post-stroke. The infection group had
higher Rankin Scores even when non-surviving patients were removed,
indicating more dependency. This was maintained when patients were
split into groups based on time of infection occurrence. OR odds ratio,
CI confidence interval
Table 2 Median scores (IQR) for
Barthel Index and Health Utility
State (HUS) in the comparison of
stroke patients with infection and
all other patients at defined time
points
Group n Barthel HUS
All patients Infection 209–212 −5 (−5 to 30)* 0.00 (0.00–0.03)*
Other patients 2995–3009 85 (50 to 100) 0.64 (0.19–0.81)
Surviving patients Infection 94–97 35 (8 to 75)* 0.03 (−0.10 to 0.59)*
Other patients 2798–2812 90 (60 to 100) 0.66 (0.26 to 0.81)
Between 1 and 7 days Infection 48–50 30 (5 to 71)* 0.03 (−0.09 to 0.59)*
Other patients 2631–2645 90 (65 to 100) 0.69 (0.26 to 0.85)
Between 8 and 28 days Infection 23–24 43 (6 to 83)* 0.03 (−0.10 to 0.59)*
Other patients 2570–2582 90 (65 to 100) 0.69 (0.26 to 0.85)
Between 29 and 76 days Infection 23 40 (20 to 80)* 0.15 (−0.09 to 0.64)
Other patients 2567–2579 90 (65 to 100) 0.69 (0.27 to 0.85)
*p < 0.05 compared to other patients
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p = 0.049). Analysis of surviving infection patients alone
showed that the timing of infection did not affect functional
outcome (OR = 1.00, 95% CI = 0.99–1.01, p = 0.47). An
additional analysis where patients with infection and patients
without SAE were paired to control for variables such as age
and stroke severity found similar results, whereby patients
with infections consistently had reduced functional outcomes
(Supplementary Figure II).
Infections at all three points were also associated with re-
duced functional outcome as measured by the Barthel Index
(1–7 days: OR = 0.54, 95% CI = 0.40–0.72, p < 0.001; 8–
28 days: OR = 0.57, 95% CI = 0.38–0.86, p = 0.007; 29–
76 days: OR = 0.53, 95% CI = 0.35–0.81, p = 0.003). When
measured using the HUS, patients with infections between 1
and 7 days post-stroke (OR = 0.62, 95% CI = 0.46–0.83,
p = 0.001) or 8–28 days post-stroke (OR = 0.66, 95%
CI = 0.43–1.00, p = 0.049) had significantly worse functional
outcome with a trend toward worse functional outcome in
patients with infection between 29 and 76 days post-stroke
(OR = 0.67, 95% CI = 0.45–1.02, p = 0.063).
Discussion
The aim of this analysis was to determine whether severe
infection at different time points post-stroke increases case
fatality and dependency at 90 days post-stroke. Our study
indicates that infections, at all time points assessed between
1 and 76 days, are associated with a higher incidence of death
or dependency at 90 days. The time of infection onset did not
alter the effect on death or functional outcome, demonstrating
that infections that develop weeks after a stroke are as detri-
mental as those occurring within the first 7 days.
This work supports the current literature showing the detri-
mental effects of infection [3–6] and of systemic inflammation
[20]. The likelihood of fatality after infection in these stroke
patients is much higher than that seen in other patient popula-
tions with pneumonia [21, 22], comparable to that after
SSRCEs. In addition, these infections are associated with poor
post-stroke recovery (independent to causing fatality) at much
later time points than those which are established in the litera-
ture [14, 15, 23]. This highlights the need for long-term consid-
eration of infections in patient care with measures to allow early
identification and treatment. Unfortunately, prophylactic antibi-
otics do not, in themselves, appear to reduce rates of pneumonia
infection, or improve functional outcome [24, 25]. Instead,
measures to reduce aspiration such as awareness, diagnosis
and management of dysphagia [26] or antiemetic treatment to
reduce vomiting/regurgitation [27] are likely be more effective
with ongoing trials hoping to address this [28]. However, no
analyses of the use of preventive measures or the incidence of
dysphagia were completed here due to lack of data.
Within this analysis, it is unclear how infections are con-
tributing to functional deficits. Previous studies have shown
that general medical complications after a stroke do influence
rates of death and disability [23, 29] and any adverse event is
likely to have some effect on functional outcome. Time is
critical when undergoing therapy, with rehabilitation being
most effective in the first 30 days post-stroke [30]. However,
the detrimental effect of later infections (from 29 to 76 days
post-stroke) means that it is likely that infections are having a
larger impact than just interfering with therapy. Mechanisms
have been suggested for the effect of infection including an
increased risk of further SAEs [31] and the development of an
autoimmune response against the brain [32]. Inflammatory
processes seem to be a likely contributor to the effect of infec-
tion. Pro-inflammatory T lymphocytes [32] and inflammatory
markers such as IL-6 [20] have both been linked to poor out-
come in stroke patients. Meanwhile, work in animal models
has shown that activation of the peripheral immune system by
lipopolysaccharide shortly after a stroke leads to increased
microglia activation and neutrophil infiltration within the
stroke infarct [33, 34] and worsens functional outcome [33,
35]. Finally, it has been shown in animal models of neurode-
generative diseases that peripheral inflammation leads to the
reactivation of microglia within the brain [36]. It is possible
that this is also occurring in stroke patients who get infections,
particularly those with infections at later time points when the
initial inflammatory responses to stroke onset are resolving.
Limitations
The strength of this study is that the data are based on a large
multinational cohort of patients with high-fidelity data collec-
tion. However, there are several limitations to this study. First,
this is a post hoc analysis of previously collected data from the
ENOS database. During its conception, the ENOS investiga-
tors did not plan to investigate the effects of post-stroke infec-
tion and only collected most of their outcomemeasures for use
as secondary outcomes [16]. This resulted in some gaps in
data potentially reducing the numbers of patients in this anal-
ysis. Therefore, only those outcome measures with sufficient
numbers of patients were used in this study.
Second, information on infection was not collected pro-
spectively but rather using SAE reports which are known to
show variability within and between sites and regions [37].
Therefore, it is possible that some SAEs were missed, partic-
ularly at later time points after hospital discharge. This is
reflected in the incidence of SAEs and infections in this pa-
tient population. Only 23.4% of patients included in the anal-
ysis developed SAEs and only 27.9% of these patients had
infections. In total, this means approximately 6.5% of patients
developed infections, a lower frequency than that generally
reported in the literature (30% on average [17]).
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Third, the reliance on SAE reports to identify infections
means that only serious infections were included in this anal-
ysis. Severity has been shown to have a role in determining
how detrimental an infection is to post-stroke recovery [2, 23]
and the fact that the effect of infection on fatality is higher than
that of some previous reports supports this [3, 4]. Because of
this, this dataset cannot be used to say that any infection is
harmful to recovery regardless of time of infection. We can
only be certain that severe infections are detrimental to func-
tional outcome irrespective of time post-stroke.
Finally, as the patients with infection are on average older
and have worse stroke severity, it is likely that their rate of
death [38] and disability [39] would be higher without the
additional complications of infection. It could be argued that
these patients developed infections because they had worse
functional outcome [40] rather than infection causing their
decline, or that these patients may be given palliative care
for their infections rather than aggressive treatment. Both of
these factors would contribute to the high levels of death and
disability. The influence of older age and stroke severity was
accounted for by their inclusion as covariates within the anal-
yses and by the use of patient pairing in an additional analysis
of functional outcomes (Supplementary Table II and
Figure II). Additionally, there is evidence at earlier time points
post-stroke [14, 15], and from other diseases [7, 8], that infec-
tion accelerates the decline of neurological function, so the
potential of infection to inhibit or limit recovery still needs
to be taken seriously.
Summary
Infection at both early (1–7 days) and later (≤76 days) time
points post-stroke is detrimental to a person’s functional re-
covery and survival from a stroke. Further work should estab-
lish whether it is possible to initiate prompt treatment of all
infections to reduce their effects on mortality and functional
outcome. In addition, work should be undertaken to investi-
gate the mechanisms by which infections lead to increased
deficits. Investigation into this area may be able to establish
time periods of particular importance in post-stroke recovery,
determine the types of infections which have the greatest in-
fluence or define the effect of post-stroke infection on a range
of functional outcomes.
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